HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Contracts For QRA Model To Determine Safe Use Levels For 26 Fragrance Allergens

This article was originally published in The Rose Sheet

Executive Summary

The ingredients at issue already must be labeled on cosmetic products in the EU due to their recognized sensitization and allergy potential. FDA expects to award the contract by the end of September, and finished work will be due to the agency within 18 months thereafter.


Related Content

CIR Expert Panel’s April Meeting: 82 Brown Algae Ingredients Reviewed; Preservative Developments; More
Industry Cautions FDA To Avoid ‘Overinterpreting’ Cosmetic Allergy Survey Results
FDA Plans Consumer Survey To Better Understand Cosmetics Allergy Prevalence
Johnson’s Leads J&J On Road To Fragrance Transparency
EU Watch: Next Steps Re Controversial CMR Ban Approach, Fragrance Allergens Labeling
FDA Contracting Out Research On 25 Cosmetic Ingredients’ Allergenicity
European Scientific Committee Not Budging On Recommended MI Restrictions
EC Proposes Tighter Regulation Of Fragrance Allergens, Ban On Three
EU cosmetic labeling





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts